INBX Inhibrx Biosciences, Inc. Insider Trading

Viking Global, 10% owner, sold 350,000 shares (77.3% of holdings) at $32.25 for $11.3M on 2025-10-07

Viking Global, a 10% stakeholder in Inhibrx, executed 3 separate sales totaling 350,000 shares for $11,287,500.00 at $32.25 on 2025-10-07, reducing its position from 452,864 shares to 102,864 shares. The current price of $35.00 places the transaction at $2.75 below today's mark, while the stock is -1.8% from its 52-week high of $35.65 and has risen 18.3% over the past 30 days and 60.8% over 90 days. Inhibrx's fundamentals are deteriorating significantly: annual revenue growth is -88.9%, the latest quarterly revenue is $1,300,000.00, net income is -$28,654,000.00, and the P/E ratio stands at 0.31. Across Viking's cross-ticker open-market history, its prior 17 sales averaged a 90-day return of -18.7% with an 82.35% well-timed rate, indicating a pattern of selling before subsequent declines; in this case, however, the stock has appreciated after the transaction, placing this sale outside the insider's typical timing pattern.

Director Kayyem Jon Faiz purchased 107,186 shares at blended average price $14.21 across 4 transactions on 2024-11-19 and 2024-11-20, investing $1,523,619.52.

Director Faiz purchased 107,186 shares totaling $1,523,619.52 at a blended average price of $14.21, a significant personal investment. However, his track record presents a cautionary pattern: across 7 prior open-market buys, the average 30-day return was -22.7% and 90-day return was -14.2%, with a 90-day win rate of 0.00%. His five prior purchases at INBX specifically showed similarly negative outcomes, with all five trades experiencing negative 90-day returns ranging from -7.4% to -20.2%. The stock is currently trading at $14.08, down 64.4% from its 52-week high of $39.56, and the company faces significant headwinds: revenue of $0.00 in the latest quarter and a net loss of $-43,864,000.00. The purchase occurs against a backdrop of consistent underperformance in this insider's prior trades and fundamental weakness at the company.

Director Vuori Kristiina buys 6,667 shares of INBX at $15.00; holdings increase 48.4% in rapid succession of buys

Director Vuori Kristiina purchased 6,667 shares at $15.00 on 2024-10-03, increasing her holdings to 20,443 shares in a transaction worth $100,005.00. This purchase marks her third buy at Inhibrx in as many weeks (prior buys on 2024-09-11 and 2024-09-10), representing a 48.4% increase in holdings over the pre-transaction level of 13,776 shares. The transaction price of $15.00 sits at a significant discount to the 52-week high of $39.56, reflecting a -61.4% decline from peak levels. Notably, her most recent prior buy at this ticker on 2024-08-29 has delivered a +10.9% return over 30 days, consistent with her cross-ticker track record of +10.9% average 30-day returns on prior buys. The rapid accumulation pattern warrants attention to underlying business developments or valuation inflection points.

CEO Lappe Mark purchased 40,000 shares at blended $15.73 on Sept 12–16; stock now $17.43, +39.9% in 30 days.

Mark Lappe, CEO of Inhibrx Biosciences, executed 2 separate purchases totaling 40,000 shares (40.0K shares) for $629,116.96 ($629.1K) between September 12–16, at prices of $15.05 and $17.13. His stake increased 6.0% to 705,548 shares. The timing is notable: the stock traded at a 52-week low near $11.04 and has since recovered +39.9% over 30 days and +19.6% over 90 days to the current $17.43 price, indicating a near-term reversal from depressed levels. Prior purchases at INBX on September 3, 6, 9, and 10 signal sustained accumulation over a narrow window, though 30-day and 90-day returns for those trades remain unmeasurable. The fundamentals present a stark anomaly: quarterly revenue of $100,000.00 against net income of $1,858,011,000.00 ($1.9B) reflects either an accounting event (e.g., non-cash gain or restructuring) or a data quality issue requiring clarification. An investor should establish whether the large net income is an operational reality or a one-time item, as it materially affects the valuation context for the CEO's accumulation pattern.

Director Kristiina Vuori bought 6,636 shares for $99,991.99 at Inhibrx in two transactions, raising holdings 92.9%.

Vuori made 2 separate purchases totaling 6,636 shares for $99,991.99, executed on consecutive trading days at prices of $15.00 and $15.07, increasing her stake from 7.1K shares to 13.8K shares. The current share price of $15.08 sits 61.9% below the 52-week high of $39.56, and the stock has recovered 33.4% over the past 30 days. Her cross-ticker track record shows only 1 prior buy with no measurable outcome history, and at Inhibrx specifically she executed an earlier buy on 2024-08-29 whose outcome remains unmeasured. The Company's fundamentals show quarterly revenue of $100,000.00 against net income of $1,858,011,000.00, indicating material losses, while the market cap stands at $218,296,632.32. This filing provides a data point on insider positioning but lacks sufficient historical pattern at this ticker to support timing inferences.

CEO Mark Lappe purchased 44,000 shares at avg $15.25 across 3 transactions in early Sept; blended with cluster of 2 other insider buys in past 14 days.

Mark Lappe, Chief Executive Officer, executed 3 separate purchases totaling 44,000 shares for $671,150.00 between September 6-10, 2024, at prices ranging from $15.19 to $15.29—near the current price of $15.18 and well below the 52-week high of $39.56. His holdings increased 7.1% to 665,548 shares post-transaction. Notably, this buying activity occurred as part of a broader cluster pattern: 2 other insiders also purchased shares within the past 14 days, and Lappe himself executed 5 additional buys at INBX during late August and early September (most recent on 2024-09-03), suggesting sustained accumulation by company leadership during a period when the stock is down 61.6% from its 52-week high. The revenue figure ($100,000.00 latest quarter) appears anomalously low relative to the $1.9B net income and $219.7M market cap, warranting deeper scrutiny into the financial health and reporting accuracy of the company fundamentals.

CEO Lappe Mark buys 40,000 shares across 4 transactions totaling $596,762.80; 3 other insiders also bought within 14 days.

Mark Lappe, Chief Executive Officer of Inhibrx Biosciences, executed 4 separate purchases totaling 40,000 shares for $596,762.80 between 2024-08-29 and 2024-09-03, raising his holdings from 125,000 to 165,000 shares (+32.0% vs pre-transaction holdings). The buys occurred at prices ranging from $14.02 to $16.31, with a blended average of $14.92, while the current price stands at $15.95—above the average transaction price. The company's latest revenue was $100,000.00 and net income was $1,858,011,000.00, though the revenue figure appears materially inconsistent with net income scale and warrants verification. A cluster pattern is present: 3 other insiders also bought within the past 14 days, concentrating insider accumulation activity during a period when the stock is -59.7% from its 52-week high of $39.56.

Director Vuori buys 7,140 INBX shares at $14.00; 3 other insiders also bought within 14 days in cluster pattern.

Director Kristiina MD Vuori purchased 7,140 shares at $14.00 on 2024-08-29, establishing an initial position in Inhibrx Biosciences. This buy occurs as part of a cluster pattern where 3 other insiders also purchased shares within the past 14 days, indicating coordinated insider interest at price levels well below the 52-week high of $39.56. The current price of $15.95 represents -59.7% from the 52-week high, placing this purchase in a depressed valuation window. The multi-insider activity within a compressed timeframe warrants analysis of whether this reflects material information unavailable to public markets or routine portfolio adjustments by board members.

Director Kimberly Manhard buys 10.0K shares of INBX at $13.98; stock down 63.2% from 52-week high. Cluster buy with 3 other insiders in 14 days.

Director Kimberly Manhard purchased 10,000 shares at $13.98, establishing an initial position after holding none previously. The purchase occurs against a backdrop of sharp stock weakness—the stock trades at $14.56, representing a 63.2% decline from the 52-week high of $39.56. Notably, this transaction is part of a cluster pattern: 3 other insiders have also purchased shares within the same 14-day window, which may indicate coordinated or consensus-driven buying by the board/management tier. The 90-day price trend of -10.4% suggests ongoing downward pressure, though the recent 30-day change of +0.3% signals stabilization. Investors should monitor whether this cluster buying reflects informed conviction in fundamental recovery or simply opportunistic accumulation at depressed levels, and track whether the stock sustains the recent price stabilization.

Director Forsyth Douglas purchased 75,000 shares across 2 transactions for $1,037,328.16, increasing stake by 50.1% amid -64.8% decline from 52-week high.

Forsyth Douglas, a director at Inhibrx Biosciences, executed 2 separate purchases totaling 75,000 shares for $1,037,328.16 on August 22-23, 2024, at prices of $12.89 and $14.07, raising his post-transaction holdings to 224,564 shares from 149,564 shares. This 50.1% increase in his equity stake is noteworthy given that the stock is currently trading at $13.93, down 64.8% from its 52-week high of $39.56 and down 59.4% over the past 90 days. The material accumulation at depressed levels—within the lower half of the 52-week range—by a director represents a substantial commitment of personal capital during a period of significant price deterioration, though the company's reported financials show extreme disparity (Revenue $100,000.00 for the latest quarter against Net income of $1,858,011,000.00), which warrants scrutiny regarding the data's consistency and the business's actual financial condition.